Related Experiment Video
Updated: May 14, 2026

In vivo Imaging of Optic Nerve Fiber Integrity by Contrast-Enhanced MRI in Mice
Published on: July 22, 2014
Visual hallucinations treated with the reinitiation of memantine in a patient with Lewy body dementia
Monica L Mathys1, Jamie McCarrell, Rebecca B Sleeper
1School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA. monica.mathys@ttuhsc.edu
Objective:
To report on a patient with Lewy body dementia who developed worsening of hallucinations with memantine withdrawal and significant improvement with reinitiation of the drug.
Case Summary:
A 78-year-old man presented to a geriatric psychiatry clinic in March 2011. The patient had experienced gradual memory loss since 2007 and was diagnosed with dementia with Lewy bodies (DLB) in 2009. His medication regimen included donepezil and memantine; his cognitive and functional status appeared stable. Occasional mild visual hallucinations occurred but were not concerning to the patient or his wife. The patient did well to July 2011, when memantine became restricted within the health care institution; memantine was therefore tapered to discontinuation. From July to September 2011, the patient's cognition and function appeared to decline significantly. He also began experiencing severe visual hallucinations daily. Memantine was reinitiated in September 2011 and, within days, the patient was free of hallucinations. By November 2011, his cognition and function were noted to have improved to previous status, and hallucinations were rare.
Discussion:
Three small randomized studies and 4 case reports were found addressing the use of memantine for DLB. Both improvement and worsening of hallucinations were noted with memantine use in the case reports, but the studies showed only a small benefit in cognition. However, cognitive and psychiatric symptoms worsened when memantine was discontinued. One study found that Neuropsychiatric-Inventory scores and hallucination scores improved significantly for patients taking memantine.
Conclusions:
The literature investigating the use of memantine for the psychiatric symptoms of DLB is limited but there are data noting results similar to what we observed in our patient when his memantine was discontinued and reinitiated.
Insights
Discontinuing memantine in a patient with dementia with Lewy bodies (DLB) led to worsening hallucinations and cognitive decline. Reintroducing memantine rapidly improved these symptoms, highlighting its potential role in managing DLB psychiatric symptoms.
Area of Science:
- Neurology
- Psychiatry
- Pharmacology
Background:
- Dementia with Lewy bodies (DLB) is a progressive neurodegenerative disorder.
- Psychiatric symptoms, including hallucinations, are common in DLB.
- Memantine is an NMDA receptor antagonist used in Alzheimer's disease, with limited investigation in DLB.
Observation:
- A 78-year-old man with DLB experienced stable cognitive and functional status on donepezil and memantine.
- Upon memantine withdrawal due to institutional restrictions, the patient showed significant cognitive decline and severe visual hallucinations.
- Reinitiation of memantine resulted in rapid resolution of hallucinations and improvement in cognition and function.
Findings:
- Memantine withdrawal was associated with a marked exacerbation of psychiatric and cognitive symptoms in a DLB patient.
- Reintroduction of memantine led to a significant and rapid improvement in hallucinations and overall status.
- Existing literature, though limited, suggests memantine may benefit psychiatric symptoms in DLB.
Implications:
- Memantine may play a crucial role in managing psychiatric symptoms, particularly hallucinations, in patients with DLB.
- Abrupt discontinuation of memantine could precipitate severe symptom exacerbation in DLB patients.
- Further research is warranted to establish the efficacy and optimal use of memantine for DLB management.
Related Concept Videos
Alzheimer's Disease: Treatment
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Dementia l: Introduction
